Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Sequencing of antiretroviral therapy in children in low- and middle-income countries.

Sohn AH, Nuttall JJ, Zhang F.

Curr Opin HIV AIDS. 2010 Jan;5(1):54-60. doi: 10.1097/COH.0b013e3283339bd8. Review.

PMID:
20046148
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Current and future management of treatment failure in low- and middle-income countries.

Boyd MA.

Curr Opin HIV AIDS. 2010 Jan;5(1):83-9. doi: 10.1097/COH.0b013e328333b8c0. Review.

PMID:
20046152
4.

Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options.

De Luca A, Prosperi M, Bracciale L.

Curr Opin HIV AIDS. 2010 Jan;5(1):27-37. doi: 10.1097/COH.0b013e328333ad45. Review.

PMID:
20046145
5.

Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.

De Luca A, Hamers RL, Schapiro JM.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S63-9. doi: 10.1093/infdis/jit109. Review.

PMID:
23687291
6.

Current and future antiretroviral treatment options in paediatric HIV infection.

Giaquinto C, Morelli E, Fregonese F, Rampon O, Penazzato M, de Rossi A, D'Elia R.

Clin Drug Investig. 2008;28(6):375-97. Review.

PMID:
18479179
7.
8.
9.

Early versus deferred antiretroviral therapy in children in low-income and middle-income countries.

Puthanakit T, Bunupuradah T.

Curr Opin HIV AIDS. 2010 Jan;5(1):12-7. doi: 10.1097/COH.0b013e3283339b27. Review.

PMID:
20046143
10.

Current concepts in antiretroviral therapy failure.

del Rio C.

Top HIV Med. 2006 Aug-Sep;14(3):102-6. Review.

11.

Triple nucleoside reverse transcriptase inhibitor therapy in children.

Handforth J, Sharland M.

Paediatr Drugs. 2004;6(3):147-59. Review.

PMID:
15170362
12.

HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.

Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TF.

Lancet Infect Dis. 2011 Oct;11(10):769-79. doi: 10.1016/S1473-3099(11)70141-4. Epub 2011 Aug 25. Review.

PMID:
21872531
13.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
14.

Antiretroviral therapy. Sequencing antiretrovirals.

MacArthur RD.

AIDS Read. 2000 Jun;10(6):359-64. Review.

PMID:
10881367
15.

Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview.

Bartlett JA, Buda JJ, von Scheele B, Mauskopf JA, Davis EA, Elston R, King MS, Lanier ER.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):323-31. Review. Erratum in: J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):381.

PMID:
16540933
16.

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

Wainberg MA, Sawyer JP, Montaner JS, Murphy RL, Kuritzkes DR, Raffi F.

Antivir Ther. 2005;10(1):13-28. Review.

PMID:
15751760
17.
18.

Understanding transmitted HIV resistance through the experience in the USA.

Taiwo B.

Int J Infect Dis. 2009 Sep;13(5):552-9. doi: 10.1016/j.ijid.2008.10.008. Epub 2009 Jan 10. Review.

19.
20.

Drug resistance in non-subtype B HIV-1.

Kantor R, Katzenstein D.

J Clin Virol. 2004 Mar;29(3):152-9. Review.

PMID:
14962783

Supplemental Content

Support Center